Developing a new therapeutic category:
Reperfusion-Protective Medicine.
We’re unlocking a breakthrough class of medicines with the potential to transform care. These therapies improve heart-attack recovery, prevent acute kidney injury in high-risk surgeries, and extend organ viability for transplant.
About Us
AIRR Therapeutics (Aiding Ischemic Reperfusion Recovery) is a Fannin portfolio company based in Houston, focused on tackling the unmet needs of ischemia-reperfusion injury across multiple therapeutic areas.
Our lead candidate, DMX-5804, targets key stress-response pathways activated during reperfusion, reducing tissue damage and improving organ recovery.
Across all three initial use cases, DMX-5804 complements current standards of care by addressing the underlying drivers of reperfusion injury that existing interventions cannot.
By closing this long-standing gap in reperfusion medicine, AIRR also opens the door to future expansion into other high-burden, reperfusion-mediated conditions.
Because reperfusion injury drives downstream complications, AIRR’s approach has potential to improve both acute outcomes and long-term organ function.
Innovation
AIRR is innovative because we target the common biochemical driver of reperfusion injury across the heart, kidneys, and transplanted organs.
Current standards of care restore blood flow, prevent rejection, or stabilize renal function, but none address the sudden oxidative and inflammatory surge triggered at reperfusion. AIRR directly targets this unmet gap. This unlocks:
Cross-organ biological consistency
Meaningful improvement in short- and long-term outcomes
A scalable, platform-like therapeutic strategy
A broad, multi-indication opportunity